Liver Transplantation Clinical Trial
Official title:
A Randomized Clinical Study of Retrograde Caval or Antegrade Portal Reperfusion for Early Graft Dysfunction Prevention in Deceased Brain Dead Donor Liver Transplantation
To evaluate whether retrograde caval reperfusion of liver graft could be superior over
antegrade portal reperfusion in regard of incidence and severity of early allograft liver
dysfunction.
All eligible enrolled liver transplant candidates will be randomized to receive either:
1. retrograde caval, followed by sequential portal-arterial, reperfusion or
2. antegrade, sequential portal-arterial reperfusion.
We hypothesize that retrograde caval reperfusion could be superior over antegrade portal
reperfusion in regard of incidence and severity of early allograft liver dysfunction.
Chi-square method of sample size estimation with a=0,05, b=0,20 and P1-P2 = 0,25 required a
41 subject per group (Stephen B Hulley, Steven R Cummings, Warren S Browner, Deborah G
Grady, Thomas B Newman.-4th ed. Lippincott Williams & Wilkins, 2013).
After signing the informed consent 90 patients will be randomized to study and
active-control group (45 each).
Only patients undergoing classical technique (retrohepatic IVC resection) of liver
transplantation without vena-venous bypass will be enrolled to the study.
In the study group after completion of both caval anastomoses (super and infra-hepatic) the
infra-hepatic cava-clamp is released and removed allowing the filling and flushing the liver
retrogradely through the hepatic veins. 300 ml of blood is drained via donor portal vein and
the vein will be clamped.
Suprahepatic cava-clamp is released and removed allowing venous return to the right atrium.
Portal vein anastomosis will be constructed. Before the last 2-3 stitches another 100 ml
will be drained retrogradely. Recipient portal vein clamp is removed and liver will be
reperfused antegradely. After that arterial and biliary anastomoses will be constructed.
In the control group cava-clamps are not removed until completion the portal vein
anastomosis.
Chi-square test and regression analysis will be used to test the difference in incidence of
early allograft liver dysfunction in the study groups.
Mann-Whitney test will be used to compare the median of highest aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels 24 and 48 hours post-reperfusion.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04180735 -
Intestinal Perforation in Patients Receiving an Orthtopic Liver Transplantation in the Montpellier University Hospital
|
||
Completed |
NCT01011205 -
Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation
|
Phase 3 | |
Completed |
NCT01888432 -
Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
|
Phase 3 | |
Recruiting |
NCT04203004 -
HOPE With Cytokine Filtration in Liver Transplantation (Cyto-HOPE)
|
N/A | |
Recruiting |
NCT04564313 -
Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation
|
Phase 1 | |
Withdrawn |
NCT03596970 -
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
|
Phase 3 | |
Not yet recruiting |
NCT02544906 -
Propofol Versus Dexmedetomidine for Prevention of Sevoflurane Agitation in Recipients of Living Donor Liver Transplantation
|
N/A | |
Completed |
NCT03133065 -
Early Treatment of Recurrent HCV- Infection Post Liver Transplantation in the Era of DAAs
|
Phase 4 | |
Recruiting |
NCT01705015 -
Organ Transplantation Rehabilitation: Effect of Bedside Exercise Device and Activity Reinforcement
|
N/A | |
Completed |
NCT01655563 -
Pharmacogenetic Trial of Tacrolimus After Pediatric Transplantation
|
Phase 2 | |
Terminated |
NCT01445236 -
Pilot Study of Immunosuppression Drug Weaning in Liver Recipients Exhibiting Biomarkers of High Likelihood of Tolerance
|
N/A | |
Completed |
NCT01425385 -
Autoregulation Assessment During Liver Transplantation
|
N/A | |
Completed |
NCT00938860 -
Sustained Virological Response (SVR) to Antiviral Treatment of Liver Transplant Recipients With Recurrent Hepatitis C
|
Phase 4 | |
Completed |
NCT00531921 -
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
|
N/A | |
Terminated |
NCT00585858 -
Cytokine Kinetics Test to Assess the Presence or Absence of Tolerance in Organ Transplant
|
N/A | |
Withdrawn |
NCT00585429 -
Evaluation of Kidney Disease in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00456235 -
Reduction in the Risk of Rejection by Mycophenolate Mofetil Dose Adjustment in Liver Transplant Patients With Side Effects Caused by the Calcineurine Inhibitors
|
Phase 4 | |
Recruiting |
NCT00147459 -
Immunogenicity of Booster Hepatitis B Vaccines in Children After Liver Transplantation
|
N/A | |
Terminated |
NCT00161356 -
Ambisome in Liver Transplant Patients
|
Phase 4 | |
Withdrawn |
NCT00167492 -
Enteric Coated Myfortic for Liver Transplant Recipients
|
Phase 4 |